文献速递肝病消化道肿瘤与早癌

GALAD在肝硬化队列中对肝细胞癌监测显示高敏感性

GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
PubMed 文献 · Hepatology · 2021-12-17

该研究在397例Child-Pugh A或B级肝硬化患者的前瞻性队列中,采用前瞻性标本采集、回顾性盲法评估设计,比较GALAD、纵向GALAD、HES算法与AFP对肝细胞癌(HCC)的检测性能。中位随访2.0年,42例发生HCC(57.1%早期),纵向GALAD的c-statistic最高(0.85),在特异性固定90%时纵向GALAD敏感性66.7%,高于单次GALAD的54.8%和AFP的40.5%。

要点

  • 纵向GALAD对HCC检测的c-statistic为0.85,高于单次GALAD、AFP和HES。
  • 特异性固定90%时,纵向GALAD敏感性66.7%,单次GALAD 54.8%,AFP 40.5%。
  • 对早期HCC,纵向GALAD敏感性69.2%,单次GALAD 53.8%。

核心结论

  • GALAD在肝硬化患者队列中对HCC检测表现出高敏感性,但需在大型3期数据集中验证。

研究设计与样本

  • 前瞻性队列中397例Child-Pugh A或B级肝硬化患者,采用前瞻性标本采集、回顾性盲法评估设计。
  • 患者随访至发生HCC、肝移植、死亡或失访,中位随访2.0年,42例发生HCC(57.1%早期)。

主要发现

  • 纵向GALAD的c-statistic为0.85(95% CI 0.77-0.92),高于单次GALAD的0.79(95% CI 0.71-0.87)、AFP的0.77(95% CI 0.69-0.85)和HES的0.76(95% CI 0.67-0.83)。
  • 特异性固定90%时,单次GALAD和纵向GALAD的HCC敏感性分别为54.8%和66.7%,AFP为40.5%。
  • 限制在HCC诊断前6个月内进行生物标志物评估的患者中,单次GALAD敏感性72.0%,纵向GALAD 64.0%。
  • 单次GALAD和纵向GALAD对早期HCC的敏感性分别为53.8%和69.2%。

临床怎么用

  • 在肝硬化患者HCC监测中,GALAD可能较AFP提高检测敏感性,尤其纵向GALAD对早期HCC敏感性更高。

局限性

  • 研究结论需在大型3期数据集中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Most patients with HCC are diagnosed at a late stage, highlighting the need for more accurate surveillance tests. Although biomarkers for HCC early detection have promising data in Phase 2 case-control studies, evaluation in cohort studies is critical prior to adoption in practice. We leveraged a prospective cohort of patients with Child-Pugh A or B cirrhosis who were followed until incident HCC, liver transplantation, death, or loss to follow-up. We used a prospective specimen collection, retrospective, blinded evaluation design for biomarker evaluation of GALAD (gender × age × log alpha-fetoprotein [AFP] × des-gamma-carboxy prothrombin), longitudinal GALAD, and the HCC Early Detection Screening (HES) algorithm-compared to AFP-using patient-level sensitivity and screening-level specificity. APPROACH AND RESULTS: Of 397 patients with cirrhosis, 42 developed HCC (57.1% early stage) over a median of 2.0 years. Longitudinal GALAD had the highest c-statistic for HCC detection (0.85; 95% CI, 0.77-0.92) compared to single-time point GALAD (0.79; 95% CI, 0.71-0.87), AFP (0.77; 95% CI, 0.69-0.85), and HES (0.76; 95% CI, 0.67-0.83). When specificity was fixed at 90%, the sensitivity for HCC of single-time point and longitudinal GALAD was 54.8% and 66.7%, respectively, compared to 40.5% for AFP. Sensitivity for HCC detection was higher when restricted to patients with biomarker assessment within 6 months prior to HCC diagnosis, with the highest sensitivities observed for single-time point GALAD (72.0%) and longitudinal GALAD (64.0%), respectively. Sensitivity of single-time point and longitudinal GALAD for early-stage HCC was 53.8% and 69.2%, respectively. CONCLUSION: GALAD demonstrated high sensitivity for HCC detection in a cohort of patients with cirrhosis. Validation of these results is warranted in large Phase 3 data sets.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Singal AG, Tayob N, Mehta A, et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2021. PMID: 34618932. doi:10.1002/hep.32185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。